Pfizer just cut a headline-grabbing deal with Donald Trump to slash drug prices under “TrumpRx,” betting political goodwill is worth thinner margins. At the same time, it’s swinging big with a $7B obesity drug acquisition, fighting to catch up with Novo Nordisk and Eli Lilly. Add in fresh COVID vaccine results — and over 1,300 lawsuits tied to Depo-Provera — and Pfizer looks like a company juggling huge risks and opportunities.